MedTrace Logo

OLE Study for Patients With Parkinson's Disease With Dementia Enrolled in Study ANAVEX2-73-PDD-001

NCT04575259 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 132

Last updated 2022-08-01

No results posted yet for this study

Summary

This is a Phase 2 open-label extension study to evaluate the effects of ANAVEX2-73 on safety and efficacy of daily treatment.

Conditions

  • Parkinson Disease Dementia

Interventions

DRUG

ANAVEX2-73

Oral capsules

Sponsors & Collaborators

  • Anavex Australia Pty Ltd.

    collaborator INDUSTRY

  • Anavex Germany GmbH

    collaborator INDUSTRY

  • Anavex Life Sciences Corp.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-10
Primary Completion
2022-05-31
Completion
2022-06-30

Countries

  • Australia
  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04575259 on ClinicalTrials.gov